Acer Therapeutics — Investor Presentation (September 2017)
25 slides from Acer Therapeutics's investor presentation, Sep 26, 2017
Slide 1: Acer
Acer Developing Therapeutics for the Treatment of Serious Rare Diseases with Significant Unmet Medical Needs September 2017 NASDAQ: ACER
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Acer Corporate Overview
Acer Corporate Overview Acer is a pharmaceutical company that acquires, develops and commercializes therapies for serious rare and ultra-rare diseases with significant unmet medical needs. » Headquartered: Cambridge, MA » Headcount: 7 » Founded: December 2013 » Public: September 2017 » Cash: $10M gr
Slide 4: Management Team
Management Team Management has extensive expertise in orphan development & commercialization Chris Schelling, CEO and Founder B e O M A R | N * 18 years of biotech/pharma strategic and orphan drug expertise Bob Steiner, M.D., Chief Medical Officer WA Marshfield Clinic Pediatrician / metabolic geneti
Slide 5: Investment Highlights
Investment Highlights “Rhe Lead Program (EDSIVO™) is a New Chemical Entity for treatment of Vascular Ehlers-Danlos Syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of potential launch ACER-001 for treatment of Urea Cycle Disorders (UCD) and
Slide 6: Clinical Pipeline
Clinical Pipeline Novel MOA / Phase Phase Phase Program / Indication ; oe NDA Unique Characteristics 1 2 3 EDSIVO™ (celiprolol) VEDS (COL3A1#) Improves hemodynamic stability; decreases vascular resistance ACER-001 (reformulated sodium phenylbutyrate) ucD Comparable to Buphenyl; taste-masked MSUD Inh
Slide 7: EDSIVO Overview
EDSIVO™ Overview Vascular Ehlers-Danlos syndrome (vEDS) EDSiIvo™ Product Profile The Opportunity Acer *Rherapeutics Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and
Slide 8: Vascular Ehlers-Danlos Syndrome (vEDS)
Vascular Ehlers-Danlos Syndrome (vEDS) Ehlers-Danlos Syndrome (EDS) are a group of hereditary disorders of connective tissue » Vascular EDS (vEDS, EDS type IV) is the severe subtype: Characterized by aneurysms, dissections, ruptures Vascular Gastrointestinal Uterine Diagnosed by clinical symptoms an
Slide 9: Vascular Ehlers-Danlos Syndrome (vEDS)
Vascular Ehlers-Danlos Syndrome (vEDS) “In vascular EDS the body lacks sufficient type III collagen, a molecule that contributes to the strength of the skin, intestines, uterus, and most importantly, the blood vessels. “People with vascular EDS live with the knowledge that they will die from this co
Slide 10: EDSIVO Unique Mechanism of Action
EDSIVO™ Unique Mechanism of Action EDSIVO™ is the only agent to show clinical benefit in patients with vVEDS EDSIVO™ has a very unique pharmacological profile: Selective B1 and a2 adrenergic receptor antagonist £2 and B3 adrenergic receptor agonist, Intrinsic sympathomimetic activity (ISA+) Lacks no
Slide 11: EDSIVO Pivotal Clinical Trial
EDSIVO™ Pivotal Clinical Trial Acer herapeutics Multicenter, prospective, randomized, open trial with blinded endpoint assessment 9 sites: eight in France, one in Belgium Inclusion criteria adapted Villefranche diagnostic criteria: 1 major criterion and 2 minor criteria, or 4 minor criteria needed f
Slide 12: Results & Analysis
* Results & Analys' Trial stopped early for treatment benefit (mean follow-up 47 months) The primary endpoint (arterial dissection or rupture) affected 5 (20%) celiprolol patients and 14 (50%) controls (hazard ratio [HR] 0.36; p=0.04) Primary and secondary endpoints (intestinal or uterine rupture) a
Slide 13: EDSIVO vEDS Patient Registry
EDSIVO™ vEDS Patient Registry Paris (AP-HP) Registry Pls: Michael Frank, Xavier Jeunemaitre 148 patients enrolled in registry 100% of patients in registry have COL3A1 gene mutation >80% of patients on celiprolol Study Period: Jan. 2000 to Dec. ‘14 (for initial referral patients), followed until 2017
Slide 14: EDSIVO Regulatory Plan
EDSIVO™ Regulatory Plan + Pivotal Clinical Trial + n=53 patients (62% COL3A1+) + — Statistically-significant improvement in 1° endpoint EFS (p=0.04) + Paris Registry: + n= 148 patients (100% COL3A1+) + >80% patients on celiprolol + Sanofi MHRA Dossier + >13,000 pages (220 studies) + Pharmacology, PK
Slide 15: vEDS Market Sizing
vEDS Market Sizing vEDS Patient Population for basis of market sizing = 4,169 patients 2 instances of the EDS Dx Code 756.83 separated by = 2 months Includes at least one other Dx or CPT code relevant to vVEDS -AND- Excludes hypermobility syndrome vEDS Patients (Rank) Name ‘New York Newark-Jersey Ct
Slide 16: Accelerate Diagnosis
Accelerate Diagnosis Broad Familial Genetic Testing Program Facial Recognition Program According to HVH, there are ~4,000 to 5,000 patients with vEDS in the U.S. According to genetic labs, ~2,000 patients have had a genetic test that confirms COL3A1 status Abroad genetic testing program for COL3A1 (
Slide 17: vEDS Patient and Payer Demographics
vEDS Patient and Payer Demographics Age Distribution “| sl Freconarn Gender Distribution a dw = H Sa | a = Male a | I Feria 7 rey oe ry “ Q There is a higher number of patients in the Payer Distribution’ 48-34 age group which is consistent with ax literature (Pepin et al., 2000) Q Greater distributi
Slide 18: EDSIVO Proposed Commercial Strategy
EDSIVO™ Proposed Commercial Strategy vEDS Center of Excellence: EDSIVO™ Proposed Launch Plan » vEDS Centers of Excellence » 50 COEs at launch » Grow to 100 COEs in 3 years * ~20-50 vEDS patients / COE » Major Genetic Labs (COL3A1+) UW: 1,250 pts » CTGT/GeneDx/ARUP/Ambry » BCM/Mayo/MGH/Emory » Acer C
Slide 19: EDSIVO HEOR
EDSIVO™ HEOR BE recision HEALTH ECONOMICS » Precision Health Economics is developing a health economic (cost-consequence) model demonstrating the economic and clinical value of vVEDS Centers of Excellence, and the potential impact of EDSIVO™ on patient outcomes * These models will help quantify and
Slide 20: EDSIVO Market Opportunity
EDSIVO™ Market Opportunity » If approved, EDSIVO™ will be the only FDA-approved therapy to treat vVEDS patients * 2,000 to 5,000 vEDS patients in the U.S. * Orphan pricing well supported by initial payer research, with additional validation from HEOR models » Provide a robust patient assistance prog
Slide 21: ACER-001 Overview
ACER-001 Overview » Agroup of metabolic genetic diseases that lead to toxic build-up of NH4+ Urea Cycle Disorders » Currently treated with Ravicti, Bupheny!, Ammonul, and a highly-restricted diet (ucD) » >2,000 patients with UCD in the U.S.; ~600 patients treated with sodium / glycerol phenylbutyrat
Slide 22: ACER-001 Taste-Masked, Immediate Release
ACER-O001 Taste-Masked, Immediate Release Mouth > Stomach oO 10 20 30 40 SO 60 Time (min) Excellent protection for several minutes at mouth pH followed by rapid release at stomach pH Acer herapeutics nN aa” v v Palatability / Compliance Relatively Reasonable Orphan Pricing Acer is working closely wi
Slide 23: ACER-001 Market Opportunity
ACER-001 Market Opportunity » Cannibalize existing sodium phenylbutyrate market share in UCD » Taste-masked, immediate-release formulation » Competitively priced » U.S. barriers to entry * Orphan Drug Exclusivity: 7 years in U.S. (MSUD) » “Other” Exclusivity: 3 years in U.S. » Pediatric Exclusivity:
Slide 24: Acer Financial Overview
Acer Financial Overview » Expected to have sufficient funding through NDA filing for EDSIVO™ » $10M gross proceeds from RTO financing in September 2017 * Capitalization at mid-September 2017 » 6.5M shares of common stock » 6.6M shares of common stock fully diluted* » $28M invested to date through mi
Slide 25: Acer Summary
Acer Summary “Rhe Lead Program (EDSIVO™) is a New Chemical Entity for treatment of Vascular Ehlers-Danlos Syndrome (vEDS) with a robust data package, including survival endpoints and long-term registry data at time of launch ACER-001 for treatment of Urea Cycle Disorders (UCD) and Maple Syrup Urine
Acer Therapeutics — Investor Presentation (September 2017) on 6ix